$PCVX 8-K SEC Filings

Filed On	Filing
09 Oct 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant +1 more FIRST SUPPLEMENTAL INDENTURE, dated as of October 9, 2026, between Vaxcyte, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), to the Base Indenture (as...
05 Oct 2026	8-K: Regulation FD Disclosure; Other Events VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21)
03 Sep 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
05 Aug 2026	8-K: Results of Operations and Financial Condition
15 Jul 2026	8-K: Departure/Election of Directors or Officers; Compensation
23 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation
16 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
06 May 2026	8-K: Results of Operations and Financial Condition
24 Feb 2026	8-K: Other Events
24 Feb 2026	8-K: Results of Operations and Financial Condition
02 Feb 2026	8-K: Other Events
19 Dec 2025	8-K: Departure/Election of Directors or Officers; Compensation
04 Nov 2025	8-K: Results of Operations and Financial Condition
30 Sep 2025	8-K: Entry into a Material Definitive Agreement
06 Aug 2025	8-K: Results of Operations and Financial Condition
17 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders
07 May 2025	8-K: Results of Operations and Financial Condition
01 May 2025	8-K: Departure/Election of Directors or Officers; Compensation
31 Mar 2025	8-K: Regulation FD Disclosure; Other Events
25 Feb 2025	8-K: Results of Operations and Financial Condition

Comments